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Abstract: Cardiovascular diseases are one of the leading causes of death. Increasing evidence has
shown that pharmacological or genetic targeting of mitochondria can ameliorate each stage of these
pathologies, which are strongly associated with mitochondrial dysfunction. Removal of inefficient
and dysfunctional mitochondria through the process of mitophagy has been reported to be essential
for meeting the energetic requirements and maintaining the biochemical homeostasis of cells. This
process is useful for counteracting the negative phenotypic changes that occur during cardiovascular
diseases, and understanding the molecular players involved might be crucial for the development
of potential therapies. Here, we summarize the current knowledge on mitophagy (and autophagy)
mechanisms in the context of heart disease with an important focus on atherosclerosis, ischemic heart
disease, cardiomyopathies, heart failure, hypertension, arrhythmia, congenital heart disease and
peripheral vascular disease. We aim to provide a complete background on the mechanisms of action
of this mitochondrial quality control process in cardiology and in cardiac surgery by also reviewing
studies on the use of known compounds able to modulate mitophagy for cardioprotective purposes.
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1. Fundamental Aspects of Mitophagy
Recent decades have been characterized by robust success in efforts to reduce mortality due to heart
disease; however, heart disease remains one of the leading causes of death. Every year, approximately
18 million people around the globe die from cardiovascular diseases (CVDs) [1]. Advances in clinical
care and the identification of novel pathogenetic mechanisms and new drug targets are necessary to
reduce the acutely lethal manifestations of heart disease. Several areas of challenge have emerged as
possible platforms for designing innovative therapeutic approaches. For example, pathways involving
mitochondria play major roles in heart physiology [2]. Indeed, mitochondria constitute approximately
30–40% of the cardiomyocyte volume [3], and cardiomyocyte function is closely associated with
mitochondrial status; thus, CVDs have unsurprisingly been linked to mitochondrial dysfunction [4–6].
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Mitochondria are considered the “energy powerhouses of cells”. Within these organelles, a large
proportion of cellular adenosine triphosphate (ATP) is generated from the degradation of sugars and
long-chain fatty acids (FAs) and from the metabolism of amino acids and lipids. Cardiac mitochondria
use 60% to 90% of the energy originating from FA oxidation (FAO) as their primary energy source
(they also use glucose, pyruvate, and lactate) to improve cardiac function, whereas most other organs
use glucose as the major energy substrate [7]. Mitochondria are deeply involved in calcium (Ca2+)
handling [8–10]. Recent advances in the identification of the molecular partners regulating Ca2+
dynamics in the mitochondrial compartment have helped elucidate the critical contributions of
mitochondria to (patho) physiological conditions that rely on mitochondrial Ca2+ oscillations [11].
Mitochondria are also the primary sources of intracellular reactive oxygen species (ROS) [12]. These
dangerous species are produced in the electron transport chain (ETC) due to the partial reduction of
oxygen to superoxide by complex I and complex III and are very harmful to cells. Accordingly, ROS
activate several cell death pathways, including necrosis and apoptosis pathways; more importantly,
they also cause severe damage to DNA [13]. Mitochondria possess their own DNA (mtDNA), which
is almost exclusively maternally inherited [14,15] and consists of base pairs that constitute 37 genes
encoding 13 polypeptides essential for oxidative phosphorylation (OXPHOS) plus 22 tRNAs and two
rRNAs. Unlike nuclear DNA (nDNA), mtDNA has rudimentary DNA repair mechanisms and is
not protected by histones. Hence, mtDNA is more susceptible to ROS-induced damage than nDNA.
Indeed, the mutation rate of mtDNA has been estimated to be approximately 15-fold higher than that
of nDNA [16].
Clearly, these elements highlight the importance of preserving mitochondrial integrity.
Mitochondrial dysfunction can impact various aspects of normal cell life and ultimately induce
severe alterations that can lead to the death of the cell itself. Mitochondria have developed two different
mechanisms to maintain a healthy status and guarantee an active quality control system. In the first
mechanism, biogenesis, fission and fusion cooperate with each other to increase the mitochondrial
population under conditions of high energetic demand or to permit a damaged organelle to fuse with
a healthy mitochondrion and replace its damaged or lost components [17,18]. In brief, biogenesis
is regulated by a series of transcription factors like Transcription Factor A, Mitochondrial (TFAM),
Transcription Factor B2, Mitochondrial (TFB2M), Nuclear Respiratory Factor 1 (NRF1), Nuclear
Factor, Erythroid 2 Like 2 (NRF2), Estrogen Receptor-related Receptor-alpha (ERRs) and Peroxisome
proliferator-activated receptor Gamma Coactivator 1-alpha (PGC-1α) that ensure the maintenance of
mitochondrial mass and positively regulate other genes involved in OXPHOS, heme biosynthesis and
the import of proteins into mitochondria. Instead, fission and fusion rely on a pool of proteins mainly
localized in mitochondria, such as mitofusin (MFN) 1 and 2 in the outer mitochondrial membrane
(OMM) and optic atrophy 1 (OPA1) in the inner mitochondrial membrane (IMM), which are needed
for the fusion of mitochondrial membranes and mtDNA exchange, and dynamin-related protein 1
(DRP1) and fission mitochondrial 1 (FIS1), which allow mitochondrial division, especially for the
transmission of mitochondria to daughter cells in mitosis. In healthy cells, the mitochondrial network
is highly interconnected, and there is a balance between the two mechanisms: impaired fusion leads to
mitochondrial fragmentation, and unbalanced fission leads to mitochondrial elongation.
In contrast, the second mechanism is expected to remove damaged organelles. This mainly occurs
through a cellular mechanism referred to as mitochondrial autophagy (mitophagy, Figure 1) [19].
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Figure 1. Molecular routes of mitophagy. Schematic representation of mitochondrial fate during 
mitophagy (upper panel). Representation of rearrangements of effectors onto the OMM in response 
to stress stimuli (lower left panel) and participants in the recruitment of the phogophore around the 
OMM (lower right panel) during mitophagy. OMM, outer mitochondrial membrane; FUNDC1, 
FUN14 Domain Containing 1; BNIP3, BCL2/adenovirus E1B 19 kDa protein-interacting protein 3; 
NIX, NIP-3-Like Protein X; PINK1, PTEN-induced kinase 1; PARKIN, Parkin RBR E3 Ubiquitin 
Protein Ligase; NDP52, Nuclear Domain 10 Protein 52; OPTN, Optineurin; LC3, Microtubule 
Associated Protein 1 Light Chain 3. 
First described over 50 years ago, autophagy is responsible for the sequestration and 
degradation of cytosolic components via the lysosomal pathway. During this conserved and 
physiologic process, a double-membrane vesicle (autophagosome) engulfs cellular material and then 
fuses with a lysosome to degrade it [20]. When discovered, autophagy was thought to be a nonspecific 
process in which cytosolic material was randomly sequestered. Autophagy has also been described as 
a selective mechanism capable of targeting viruses and bacteria (xenophagy), portions of the 
endoplasmic reticulum (ER; reticulophagy), peroxisomes (pexophagy) and mitochondria 
(mitophagy) [21]. 
Among the types of autophagy, mitophagy has become the most described and studied. Several 
conditions (cellular differentiation, fertilization, oxygen deprivation) and molecules (drugs and 
proteins) modulate this process. Furthermore, variations in the levels of mitophagy have been found 
in a diverse array of human pathologies, including cancer, neurodegeneration and CVDs [22]. 
Mitophagy was first observed in yeast, when two independent research groups screened for 
mitophagy-deficient mutants and identified the autophagy-related gene 32 (Atg32), which is essential 
for mitophagy. Previous studies have suggested that the gene products of Aup1p and Uth1p are 
involved in the autophagic degradation of mitochondria [23,24]; however, these factors were not 
identified during genomic screening. In mammals, the first observation of mitophagy was made 
during the maturation of reticulocytes. Mature red blood cells are devoid of mitochondria because 
immature red blood cells lose their mitochondria via mitophagy during differentiation. This event is 
mediated by the OMM protein BCL2/Adenovirus E1B 19 KDa Protein-Interacting Protein 3-Like 
(BNIP3L; also known as NIP-3-Like Protein X, NIX), whose expression increases during maturation. 
NIX contains a motif required for binding to microtubule-associated protein 1 (MAP1) light chain 3 
(LC3) [25,26], which is localized on the surface of the autophagosomal membrane and mediates the 
sequestration of mitochondria into autophagic vesicles. Subsequent studies have found that 
Nix/BNIP3L shares 50% homology with BCL2 Interacting Protein 3 (BNIP3) [27]. Interestingly, this factor 
Figure 1. olecular routes of itophagy. Sche atic representation of itochondrial fate during
itophagy (upper panel). epresentation of rearrange ents of effectors onto the in response
to stress sti li (lower left panel) and participants in the recruitment of the phogophore around
the OMM (lower right panel) during mitophagy. O M, outer itochondrial e brane; ,
o ain Containing 1; BNIP3, BCL2/adenovirus E1B 9 kDa protein-interacting protein 3; NIX,
IP-3-Like Protein X; PINK1, PTEN-induced kinase 1; PARKIN, Parkin RBR E3 Ubiquitin Protei
Ligase; NDP52, uclear Domain 10 Protein 52; OPTN, Optineurin; LC3, Microtubule Ass ciated
Protein 1 Light Chain 3.
i described over 50 years ago, aut phagy is responsible f r the seques ration and degradation
of cytosolic components via the lysosomal pathway. During this conserved and physi logic process,
a double-membrane vesicle (autophagosom ) engulfs cellular mat rial and th n fuses with lysosome
to degrade it [20]. When discovered, autophagy was thought to be a nonspecific process in which
cytosolic material was randomly sequestered. Autophagy has also been described as a selective
mechan sm capable of targeting viruses a d bacteria (xenophagy), portions of the endoplasmic
reticulum (ER; ophagy), perox somes (pexophagy) and mitochondri (mitophagy) [21].
Among the types of autophagy, mitophagy has become the most described and studied. Several
conditions (cellular differentiation, fertilization, oxygen deprivation) and molecules (drugs and proteins)
modulate this process. Furthermore, variat ons in the lev ls of mitophagy have been found in a diverse
array of human pathologies, including cancer, neurodegeneration and CVDs [22].
Mitophagy was first observed n yeast, when two i depende t esearch group screened for
mitophagy-deficient mutants and i e tifi d he autophagy-related gene 32 (Atg32), which is ssential
for mitophagy. Previo s studies have suggested that the gene products of Aup1p and Uth1p are
involved in the autophagic egradation of mitochondria [23,24]; however, these factors were not
dentified during genomic screening. In ma mals, the first observation of mitophagy was made
during the maturation of reticulocytes. Mature red blood cells ar dev id c ondria becaus
immature red blood cells lose their mitochondria via mitophagy during ifferentiation. This event
s ediated by the OMM protein BCL2/Adenovirus E1B 19 KDa P otein-Interacting Protein 3-Like
(BNIP3L; also known as NIP-3-Like Protein X, NIX), whose expressi n i creases during maturation.
NIX contains a motif required for binding to microtubule-associated protein 1 (MAP1) light chain
3 (LC3) [25,26], wh ch is localized o the surface f the autoph gosomal membrane and mediates
the sequestration of mitochon ria into autophagic vesicles. Subsequent studies have found that
J. Clin. Med. 2020, 9, 892 4 of 26
Nix/BNIP3L shares 50% homology with BCL2 Interacting Protein 3 (BNIP3) [27]. Interestingly, this
factor is involved in autophagy and mitophagy under hypoxic conditions both in cancer and during
myocardial ischemia/reperfusion (I/R) injury (IRI) [28,29]. These findings suggest that mitophagy
in mammals may be a mechanism conserved across various cell types and not only in reticulocytes.
Accordingly, mitophagic elements have been unveiled in all human tissues, and a specific molecular
mechanism governing mitophagy has been found. The discovery of this cellular pathway arose from
research on Parkinson’s disease [30,31], which revealed a particular form of recessive Parkinsonism
characterized by mutation in two genes: Parkin RBR E3 Ubiquitin Protein Ligase (PARK2), which
codes for a cytosolic E3 ubiquitin ligase named Parkin, and PTEN-induced kinase 1 (PINK1), whose
protein product is a kinase localized on the mitochondrial surface [32,33].
Normally, PINK1 enters mitochondria through the activity of translocase of the outer membrane
(TOM) and reaches the mitochondrial inner membrane through the activity of translocase of the inner
membrane (TIM), which recognizes an amino-terminal mitochondrial targeting sequence. During these
importing steps, PINK1 is subjected to a series of proteolytic cleavage events by the intermembrane
serine protease presenilin-associated rhomboid-like protein (PARL), and the full-length form of 64 kDa
is sequentially cleaved into fragments of 60 kDa and 52 kDa [34,35]. Once released in the cytosol,
the 52-kDa fragment is then degraded by the proteasome [36]. Overall, these mechanisms permit the
maintenance of very low levels of PINK1 during unstressed conditions.
When a mitochondrial population becomes damaged, the mitochondrial import of full-length
PINK1 throughout the TIM/TOM complex is disrupted; PINK1 then accumulates on the OMMs of only
injured mitochondria and is stabilized in a complex composed of TOM7, TOM40, TOM70, TOM20
and TOM22 [37,38]. PINK1 mediates two different phosphorylation events aimed at converting the
autoinhibited E3-ubiquitin (Ub) ligase Parkin into an active phospho-Ub-dependent enzyme. The first
step involves autophosphorylation at S402, S228 and T257. Interestingly, mutations in these residues
abolish both PINK1 activity and Parkin recruitment at the mitochondrial surface [39]. The second
event is the direct phosphorylation of Parkin at S65 in the N-terminal Ubl domain, which increases
its E3 ligase activity [40]. Finally, PINK1 provokes the addition of a phosphate onto S65 of Ub. As a
result of this complex regulatory mechanism, the E3 ligase activity of Parkin is activated, allowing
it to ubiquitinate mitochondrial proteins via direct interaction with phospho-Ub conjugates on the
mitochondria. The presence of these poly-Ub chains promotes the recruitment of specific Ub-binding
autophagy receptors to connect damaged mitochondria to LC3-positive phagosomes for clearance in
lysosomes. Initial studies suggested that p62/sequestosome 1 (p62/SQSTM1) was the main receptor
involved in mitophagy [41]. Subsequent studies have demonstrated that in addition to p62, at least
four other receptors, neighbor of Brca1 (NBR1), nuclear dot protein 52 (NDP52), optineurin (OPTN)
and TAX1BP1 (TBK1), are involved during the selective removal of damaged mitochondria. Despite
the large number of studies, which adaptor is effectively essential for mitophagy remains unclear [42].
Experiments performed on cell lines with penta-knockout (KO) for all five receptors have suggested
that only Nuclear Domain 10 Protein 52 (NDP52) and OPTN are effectively required for mitophagy.
However, these experiments were performed on a single cell line, and not all cell types and tissues
have comparable levels of these molecules [43].
2. Mitophagy in Cardiovascular Diseases
2.1. Atherosclerosis
Atherosclerosis (AS) is a chronic inflammatory disease that is very prevalent in industrialized
nations. The interplay among lipid accumulation, increased vascular smooth muscle cell (VSMC)
proliferation, matrix turnover, calcification and inflammation cause a significant narrowing of the
arteries because of plaque buildup inside the artery lumen. In the last 10 years, various methods have
been applied to assess autophagy in cells that form atherosclerotic plaques (VSMCs, endothelial
cells, macrophages), including electron microscopy, fluorescence microscopy and western blot
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approaches [44,45]. Studies conducted on human specimens and mouse models of AS have reported
either dysfunctional or decreased autophagy based on detection of the autophagic markers p62 and
LC3-II in cells isolated from plaques [46–48]. Indeed, a strong decrease in LC3-II expression has
been reported in patients with unstable plaques compared to those with stable plaques [48]; such
decreases would enable dead cell accumulation in the artery wall and subsequent plaque destabilization
(Figure 2). A dysfunction in the autophagic process, caused by either autophagy related 7 (ATG7)
deletion in VSMCs [49,50] or a macrophage-specific ATG5-null mutant mouse model [46], has been
linked to atheroma development in AS. In the latter, cholesterol crystals are not removed from
plaques and trigger an increased secretion of interleukin (IL)-1β after macrophage inflammasome
hyperactivation [46]. In humans and animals, complete loss of autophagy (like ATG5-null cells) is
incompatible with life, and according to some authors, a slight decrease in autophagy is not always
associated with experimental atherosclerosis [46]; therefore, further severe dysfunctions would be
expected to occur in this pathway. One of these could be progressive lysosomal impairment with a
concomitant accumulation of p62, a protein responsible for bringing polyubiquitinated proteins to the
autophagosome for lysosome-dependent degradation.
Much less is known about mitophagy in the context of AS than about mitophagy in a general sense.
Overall, mitophagy, together with fission and fusion dynamics, helps clear damaged mitochondria by
optimizing the function of the total mitochondrial population inside cells [51]. Given that ROS and
inflammation play pivotal roles in the progression of disease, activation of mitophagy by oxidized
low-density lipoprotein (ox-LDL, an atherosclerotic agent) [52] and through exogenous melatonin
administration [53] counteracts AS progression by stabilizing atherosclerotic plaques (Table 1). Indeed,
melatonin was able to modulate mitophagy via a SIRT3/FOXO3a/Parkin-dependent signaling pathway
and to attenuate IL-1β secretion.
Table 1. Summary of literature describing mitophagic pathways in cardiovascular diseases.
Pathology Mechanism of Action References
Atherosclerosis
Atherosclerotic plaque stabilization mediated by ox-LDL. [52]
NLRP3 inflammasome activation by the SIRT3/FOXO3a/Parkin signaling pathway. [53]
Ischemic heart
disease
Mitophagy is an adaptive metabolic response to hypoxia mediated by BNIP3,
Beclin-1 and ATG5. [54]
Pigment epithelium-derived factor (PEDF) protects hypoxic cardiomyocytes in a
rat model through the PEDF/PEDF-R/PA/DAG/PKC-α/ULK1/FUNDC1 pathway. [55]
Fundc1-knockout (KO) platelets present impaired mitochondria, which cause more
I/R heart injury. [56]
FUNDC1 loss of function through CK2α-mediated phosphorylation leads to the
development of cardiac I/R injury in mice. [57]
HMGB1 treatment in a murine model inhibits apoptosis via mTORC1 inhibition. [58]
Cardiomyopathies
and heart failure
Inhibition of the dynamic process through the expression of dominant-negative
Drp1 (Drp1K38A) results in disruption of mitophagy. C452F Drp1 mutation causes
spontaneous development of monogenic dilated CM.
[59]
Mice lacking transferrin receptor (Tfrc) develop lethal CM and drastically
ineffective mitophagy due to altered expression of proteins involved in mitophagy. [60]
Enhancement of mitophagy by TAT-Beclin1 attenuates the development of DCM. [61]
Melatonin inhibits Mst1 phosphorylation, increases LC3-II levels and enhances
Parkin activity in mice with CM. [62]
Parkin-deficient mice are more sensitive to MI, developing larger infarcts and
exhibiting reduced survival. [63]
An increase in BNIP3 expression is detected in adult rat hearts with chronic HF. [64]
Tamoxifen-inducible cardiac-specific Drp1-KO mice present cardiac dysfunction
and increased susceptibility to I/R linked to an accumulation of damaged
mitochondria (due to mitophagy inhibition).
[65]
Phosphorylation of Ser495 in PINK1 by AMPKα2 prevents the progression of HF. [66]
Cytosolic p53 binding to Parkin prevents its translocation to damaged
mitochondria, modulating cardiac dysfunction in HF. [67]
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Table 1. Cont.
Pathology Mechanism of Action References
Hypertension
The coexistence of obesity and HT aggravates mitochondrial dysfunction; RAAS
activation inhibits mitochondrial biogenesis. [68]
Spermidine assumption leads to a delayed onset of HT in wild-type animals by
stimulating mitophagy in cardiomyocytes, but these effects are abolished in
ATG5-KO mice.
[69]
EPCs in HT patients present mitochondrial dysfunctions linked to impairment of
the CXCR4/JAK2/SIRT5 signaling pathway and failure of angiogenic capacity. [70]
Arrhythmia Decrease in mitophagy leads to pro-arrhythmic spontaneous Ca
2+ release via








Post-cardiopulmonary bypass samples display decreased levels of mitophagy
adapters NDP52 and OPTN, decreased expression of the long form of Opa1, and
translocation of Parkin to the mitochondrial fraction.
[73]
Reperfusion after CABG surgery induces FUNDC1 dephosphorylation and
mitophagy activation, causing platelet aggregation and increased risk of
thrombosis.
[74]
Ox-LDL: oxidized low-density lipoprotein; NLRP3: Nucleotide-binding domain, leucine-rich-containing family,
pyrin domain-containing-3; SIRT3: Sirtuin 3; FOXO3a: Forkhead Box O3; Parkin: Parkin RBR E3 Ubiquitin
Protein Ligase; BNIP3: BCL2 Interacting Protein 3; ATG5: Autophagy related 5; PEDF: Pigment epithelial-derived
factor; PEDF-R: PEDF receptor; PA: palmitic acid; DAG: diacylglycerol; PKC-α: protein kinase C alpha; ULK1:
Unc-51 Like Autophagy Activating Kinase 1; FUNDC1: FUN14 Domain Containing 1; CK2α: protein kinase
CK2 alpha; I/R: ischemia/reperfusion; HMGB1: High Mobility Group Box 1; mTORC1: mammalian target of
rapamycin complex 1; CM: cardiomyopathy; TAT_Beclin1: Trans-Activator of Transcription-Beclin1; DCM: diabetic
cardiomyopathy; LC3-II: Microtubule Associated Protein 1 Light Chain 3 II; MI: myocardial infarction; HF: heart
failure; PINK1: PTEN Induced Kinase 1; AMPKα2: adenosine monophosphate protein kinase alpha 2; RAAS:
renin–angiotensin–aldosterone system; ATG5-KO: autophagy related 5-knock out; CXCR4: C-X-C Motif Chemokine
Receptor 4; JAK2: Janus Kinase 2; SIRT5: Sirtuin 5; RYR2: Ryanodine Receptor 2; mito-ROS: mitochondrial reactive
oxygen species; PVD: peripheral vascular disease; LAMP2: Lysosomal Associated Membrane Protein 2; NDP52:
Nuclear Domain 10 Protein 52; OPTN: optineurin; CABG: Coronary Artery Bypass Graft.
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Figure 2. Involvement of mitophagy in major CVDs. Schematic representation of tissue remodeling 
during atherosclerosis (AS) (upper panel), I/R (middle panel) and heart failure (HF; lower panel) with 
related alterations in mitophagy extent, cell death or tissue remodeling. CVDs, cardiovascular 
diseases; I/R, ischemia/reperfusion; MPT, mitochondrial permeability transition; HF, heart failure. 
2.2. Ischemic Heart Disease 
A consequence of AS is ischemic heart disease (IHD), where the full or partial recovery of 
myocardial function is always difficult to achieve due to severe mitochondrial impairment [54,55]. 
Events consisting of I/R phases are accompanied by oxidative stress, pH changes, and cytosolic and 
mitochondrial Ca2+ overload, which lead to the opening of the mitochondrial permeability transition 
pore complex (PTPC) and contribute to cardiomyocyte death [12,56–59]. 
Autophagy (which is activated by increased cytosolic Ca2+ concentrations [60]) and mitophagy 
are known to be features of I/R-related diseases, and ex vivo experiments on cardiac ischemia, such 
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I/R, ischemia/reperfusion; MPT, mitochondrial permeability transition; HF, heart failure.
ffi i l i ir e t [75,76].
2 overload, hich lea to the o e i f t it
t i t t i 77 80
J. Clin. Med. 2020, 9, 892 8 of 26
Autophagy (which is activated by increased cytosolic Ca2+ concentrations [81]) and mitophagy
are known to be features of I/R-related diseases, and ex vivo experiments on cardiac ischemia, such
as those performed with the Langendorff system, have made great contributions to these findings.
Lysosomal alterations were first observed in perfused rabbit hearts in 1980; after 40 min of ischemia,
the number of autophagosomes increases and peaks during reperfusion, suggesting that both ischemia
and reperfusion can induce autophagy [82]. These findings have also been replicated in the mouse
heart in vivo [83]. I/R-dependent upregulation of autophagy has been assessed by the detection
of increased LC3-II and Beclin1 protein expression in association with Bcl-2-associated athanogene
(BAG-1), a multifunctional prosurvival molecule [84]. Enhanced autophagy has also been detected
after hypoxia treatment combined with glucose deprivation and subsequent reperfusion in fetal mouse
hearts; localized lysosomal digestion limits injury to the entire cell, suggesting a role for the autophagic
process in the repair of sublethal injury [85]. Thus, autophagy appears to be an important mechanism
in cardiac tissue protection during and after hypoxia; indeed, inhibition of autophagy in animals
through wortmannin treatment impairs the induction of LC3-II formation and Beclin1 overexpression,
limiting cardioprotection [84].
In cultured cardiomyocytes, ischemia and glucose deprivation cause significant reductions in the
levels of ATP that coincide with the upregulation of adenosine monophosphate-activated protein kinase
(AMPK)-dependent autophagy and the inhibition of the mammalian target of rapamycin (mTOR)
pathway. Accordingly, transgenic mice overexpressing dominant-negative AMPK display a diminished
induction of autophagy following ischemia [83]. At the time of reperfusion, when physiological
conditions are restored, AMPK is no longer activated; thus, considering previous findings, autophagy
likely proceeds through an AMPK-independent mechanism, and some data have suggested that it
occurs via Beclin1 overexpression [83].
Statistically, autophagy and mitophagy may be classified as protective mechanisms, but this
could be an oversimplification. Under conditions in which the heart experiences energy loss, such as
ischemia, the autophagic pathway may be protective, as it preserves basal metabolic requirements;
however, induction of autophagy under other circumstances, such as at the time of reperfusion, may
be detrimental. In agreement with this hypothesis, inhibition of Beclin1 has been reported to protect
against myocyte death in vivo [83]. Other evidence has come from the use of urocortin, an endogenous
cardiac peptide previously shown to reduce other forms of myocyte cell death induced by I/R; urocortin
downregulates Beclin1 expression by activating the phosphoinositide 3 (PI3) kinase/Akt pathway [86].
Reperfusion of the heart is well accepted to lead to the opening of the PTPC [87,88]; however,
the link between the PTPC and autophagy (or mitophagy) activation is poorly understood, and the
literature remains controversial. As PTPC opening leads to mitochondrial membrane potential loss and
mitochondria depolarization, the mitophagic pathway is expected to be activated. Indeed, mitophagic
pathway activation is ascribed to PTPC opening in hepatocytes of rats and mice and in livers of
human patients [89,90], where PTPC opening also plays a role in starvation-induced mitophagy [91].
Accordingly, blockade of pore opening with the known inhibitor cyclosporine A (CsA) has been found
to prevent both mitochondrial swelling and autophagy caused by calpain 10 overexpression [92].
Moreover, overexpression of PINK1 in cardiac cells protects the cells from death by significantly
delaying the onset of PTPC opening [93]; if PINK1 is depleted, as is the case in KO animals, the heart
becomes increasingly vulnerable to ex vivo IRI. Between PTPC activity and autophagy/mitophagy, a
feedback loop may exist where each pathway, in turn, controls the other one. PTPC opening can give
rise to an autophagic-dependent cell repair mechanism when few mitochondria are involved during a
moderate insult, but this process may become inadequate under extensive damage where cells tend
to die.
On the other hand, a study headed by Gustafsson AB suggested that BNIP3-dependent mitophagy
(induced upon hypoxia and in failing hearts [94,95]) in adult cardiomyocytes does not depend on PTPC
opening [96] but only requires BNIP3 and constitutively expressed Beclin1 and autophagy related 5
(ATG5) [97].
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Additionally, ER stress and the unfolded protein response (UPR) have been associated with the
induction of autophagy and mitophagy [54,98,99]. Studies performed on both cultured neonatal rat
and adult mouse ventricular myocytes have shown activation of ER stress and UPR processes under
I/R conditions [100–102]. Indeed, hypoxia activates the UPR in surviving myocytes in the border zones
of infarcted hearts [103]. Furthermore, activation of the ER stress response was found to be involved in
the development of IHD in a predisposed transgenic murine model [104].
I/R reportedly induces excessive mitochondrial fission; this pathway can lead to the generation
of two mitochondrial populations with either increased or decreased membrane potential. Most
of the time, the depolarized population is not able to fuse and undergoes mitophagy-dependent
removal. Thus, mitophagy is dependent on mitochondrial fission; inhibition of the dynamic process
through the expression of dominant-negative Drp1K38A or through Fis1 RNA interference results in
disruption of mitophagy and subsequent accumulation of dysfunctional mitochondria [105]. Before
Drp1 moves to mitochondria to allow fission, “marked” organelles are subjected to early-stage
constriction at the mitochondria-associated membranes (MAMs), highlighting an active role for these
microdomains in the choice of division sites, the recruitment of proteins and adaptors and the fulfillment
of that process [18,106,107]. Further evidence derives from the study of inverted formin 2 (INF2), an
ER-localized protein that orchestrates upstream Drp1, actin filament rearrangement and calcium fluxes
at MAMs from the ER to mitochondria, which are essential to guarantee mitochondrial fission [108,109].
Other evidence of the cardioprotective roles of mitophagy has been described; for example, Fun14
domain-containing protein 1 (FUNDC1), a mitophagy receptor that interacts with LC3, is able to
mediate the process in response to hypoxia [55,57] and has been found to regulate mitochondrial
homeostasis, protecting the heart from IRI, in a mouse model [56]. Indeed, FUNDC1 loss of function
through casein kinase 2α (CK2α)-mediated phosphorylation leads to inhibition of mitophagy and
significant enhancement of tissue damage [110].
During in vivo acute myocardial infarction (MI) induced by permanent ligation of the left
coronary artery in transgenic mice, autophagy is enhanced to preserve cellular ATP levels and protect
cardiomyocytes from ischemic death [111] (Figure 2).
High-mobility group box-1 protein (HMGB1) is able to migrate to mitochondria and bind with
mitophagy-related proteins after exogenous administration. In vivo evidence has shown that HMGB1
treatment in a murine model of acute MI might induce cardiomyocyte survival, protecting infarcted
hearts [58]. Attenuation of apoptosis has been ascribed to the induced activation of AMPK and
inhibition of mTOR complex 1 (mTORC1) [58]. Experiments on transgenic mice with cardiac-specific
overexpression of HMGB1 have shown that the protein enhances angiogenesis, restores cardiac function,
and improves survival after myocardial infarction (MI) [112]. Autophagy inhibition in the heart,
similar to that observed upon macrophage-stimulating 1 (Mst1, a proapoptotic kinase) activation, has
been associated with p62 accumulation and aggregate formation accompanied by the disappearance of
autophagosomes and cardiac dysfunction in mice subjected to MI [113].
As introduced previously, a fine balance between all mitochondrial quality control mechanisms is
required for cell homeostasis. In IHD, a prominent role is played by mitochondrial biogenesis, the
impairment of which is responsible for the altered energy production in the heart [114]. If mitophagy
can be positively modulated (as described in Section 4) to rescue the phenotype of cardiomyocytes,
peroxisome-proliferator-activated receptor coactivator (PGC)-1α may be strongly reactivated upon
long-term exercise training to restore metabolism, although only partially [114].
2.3. Cardiomyopathies
Cardiomyopathy (CM) is a muscle-specific disorder of the heart characterized by abnormal
myocardial structure and function occurring independently of any demonstrable CVDs, such as
coronary artery disease (CAD), uncontrolled hypertension (HT), significant valvular heart disease, and
congenital heart disorders. The prevalence of CM is 3% in the global population and increases to 12%
in diabetic patients, leading to increased risks of HF and mortality [115]. Hyperglycemia, systemic and
J. Clin. Med. 2020, 9, 892 10 of 26
cardiac insulin resistance, increased free fatty acid (FFA) levels, renin-angiotensin-aldosterone system
(RAAS) activation, sympathetic dysfunction, myocardial inflammation, oxidative stress, remodeling
and fibrosis are factors that contribute to the development of CM. However, the exact pathophysiological
mechanisms remain unclear [116].
Diabetic hearts have decreased rates of glucose oxidation and increased rates of FAO,
resulting in oxidative stress, impaired OXPHOS, and eventually mitochondrial dysfunction. The
increased FAO capacity is energetically detrimental and is mediated by the enhanced activity of
peroxisome proliferator-activated receptor (PPAR)-α [117,118]. Additionally, metabolic stress-induced
mitochondrial dysfunction, enhanced ROS production and increased Ca2+ overload-induced PTPC
opening result in cardiomyocyte necrosis. Although increasing evidence has indicated that
mitochondria are pivotal players in the pathophysiology and development of CM, the mechanism still
remains to be investigated [119].
Efficient clearance of dysfunctional mitochondria through mitophagy is crucial for mitochondrial
quality control and thus for the maintenance of cardiomyocyte viability [120]. Alterations in both
autophagy and mitophagy have been extensively documented to be involved in the pathogenesis of
several CMs [121]. Notably, several studies have revealed that the process of autophagy is inhibited
in the hearts of type 1 and 2 diabetic mice, suggesting that inhibition of this process may contribute
to diabetic CM (DCM) [122–124]. Interestingly, PINK1 and Parkin protein levels are significantly
lower in type 1 diabetic hearts than in healthy hearts, leading to decreased cardiac mitophagy; this
decrease in cardiac mitophagy is correlated with reduced expression of the small GTPase Rab9,
which is involved in a noncanonical alternative selective autophagic pathway and is responsible for
mitochondrial degradation during erythrocyte maturation in the absence of ATG5 [124–126]. Recent
evidence has shown that mitochondrial dynamics play essential roles in the formation and maintenance
of cardiomyocytes [127]. One role is linked to the importance of Drp1, the small GTPase involved in
mitochondrial fission at the OMM, which is crucial for cardiac function and in response to energy
stress [59,127–129]. Indeed, Drp1 deletion in cardiomyocytes results in decreased mitophagy and
cardiac dysfunction, enhancing the risk of IRI [65,128].
Cahill TJ et al. reported that a single C452F mutation in Drp1 causes spontaneous development
of monogenic dilated CM along with a wide variety of abnormal mitochondrial defects, including
defective mitophagy [59] (Table 1). This missense mutation has been described as an enhancer of Drp1
GTPase activity that fails to guarantee the disassembly of the protein after oligomerization, thus causing
it to become a partially dysfunctional protein. In the so-called Python heart, energetic failure may be
ascribed to reduced mitochondrial Ca2+ uptake (as a consequence of ATPase Sarcoplasmic/Endoplasmic
Reticulum Ca2+ Transporting 2 (SERCA2) inactivation) and to elevated numbers of inefficient
mitochondria [59]. However, interruption of mitochondrial fusion is also related to rapid dilated CM
onset, as observed in the adult heart upon ablation of both mitofusin 1 (MFN1) and 2 [130]. This
deleterious effect is mainly attributable to a lack of fusion rather than to mitophagy dysfunction. In
addition, mice bearing heart-specific deletion of either Mfn2 [131] or Park2 with concomitant expression
of one Mfn2 mutant (a nonphosphorylatable form) [132] are predisposed to perinatal progressive CM
and death within a few weeks after birth.
Many other studies on the importance of mitophagy in CM are present in the literature. For example,
mitophagy can be considered a valid therapeutic target for transferrin receptor (Tfrc)-dependent CM,
in which mice lacking this receptor develop lethal CM and drastically ineffective mitophagy [60].
During mitophagy, mtDNA is also degraded by DNase II in lysosomes. Incomplete digestion of
mtDNA stimulates inflammation in cardiac tissue and is able to cause HF [133]. Recently, Tong M and
associates demonstrated that during high-fat diet consumption, suppression of mitophagy increases
the accumulation of lipids in the heart. The same study revealed that enhancement of mitophagy by
Trans-Activator of Transcription (TAT)-Beclin1 tends to inhibit the development of CM [61] (Table 1). In
a recent investigation, Wang S. et al. reported that mitophagy could be a target of melatonin treatment.
Indeed, melatonin inhibits Mst1 phosphorylation, increases LC3-II levels and enhances Parkin-mediated
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mitochondrial removal to counteract the negative effects of CM [63]. In line with these observations,
chronic treatment with metformin (classified as an antidiabetic and a potent inducer of autophagy),
heme oxygenase-1 (HO-1) or mitochondrial aldehyde dehydrogenase (ALDH2) prevents CM by
activating AMPK, normalizing cardiac autophagic activity, and inhibiting cardiomyocyte apoptosis
through stimulation of Mitogen-Activated Protein Kinase 8 (JNK)-Bcl-2 signaling, thereby promoting
the disruption of the Bcl-2-Beclin1 complex in diabetic heart tissue [123,134,135]. An additional
downstream event is downregulation of nucleotide-binding domain, leucine-rich-containing family,
pyrin domain-containing-3 (NLRP3) inflammasome levels in diabetic mice [136]. Interestingly, the
NLRP3 inflammasome is considered a novel molecular marker in DCM that is activated by high FFA
levels, hyperglycemia, and impaired insulin metabolic signaling.
Activation of the RAAS is considered a primary event in the etiology of both diabetes and
HT (see below). RAAS activation contributes to insulin resistance in humans and correlates with
increased levels of oxidative stress and cell death in affected hearts. Consistent with these effects
and associations, the RAAS has been found to be upregulated during the pathogenesis of DCM.
However, insulin signaling seems to have an additional role, especially at birth: inhibiting autophagy
when a newborn starts to feed. Indeed, deletion of insulin receptor genes induces excessive organelle
removal, contributing to myocyte loss and HF [137]. Overall, these findings support the importance of
auto/mitophagy in ensuring the existence of a functional network of mitochondria and suggest that
they provide cardioprotection.
2.4. Heart Failure
The 2016 European Society of Cardiology (ESC) guidelines for the diagnosis and treatment of
acute and chronic HF state that “HF is a clinical syndrome characterized by typical symptoms (i.e.,
breathlessness, ankle swelling and fatigue) that may be accompanied by signs (i.e., elevated jugular
venous pressure, pulmonary crackles and peripheral oedema) caused by a structural and/or functional
cardiac abnormality, resulting in a reduced cardiac output and/or elevated intracardiac pressures at
rest or during stress” [138].
This clinical scenario is strictly associated with mitochondrial function. To date, few studies have
focused on the specific role of mitophagy in the heart, but emerging evidence supports a protective
action for mitophagy in response to stress. Cardiomyocytes have been demonstrated to undergo
caspase-independent cell death in the context of HF, and apoptosis, oncosis, and autophagy act
simultaneously but play different roles in HF in humans [139,140].
In detail, failing hearts present impaired morphology of mitochondrial cristae, with disorganization
and reduced cristae density [141]. These structural changes have also been detected in the hearts of
Parkin-deficient mice, which exhibit disorganized mitochondrial networks and significantly reduced
mitochondrial sizes; these mice are more sensitive to MI than their wild-type littermates, developing
larger infarcts and exhibiting reduced survival. Parkin-KO cardiomyocytes present reduced mitophagy
linked to dysfunctional mitochondria after MI [62] (Table 1). Moreover, evidence from ATG5-deficient
mice has indicated that constitutive autophagy in the normal heart is a homeostatic mechanism for
maintaining cardiomyocyte size and global cardiac structure and function, while upregulation of
autophagy under HF conditions is an adaptive response to protect the heart from hemodynamic
stress [142].
As introduced in the first section and as remarked upon previously, BNIP3 is a mediator of
mitophagy and is activated during hypoxia; its effects have also been observed in an in vivo model of
chronic HF [64]. In myocytes, mitophagy is a protective response in which Drp1-mediated mitochondrial
fission and the recruitment of Parkin collaborate [143]. If disruption of Drp1 occurs, mitochondrial
elongation increases with concomitant inhibition of mitophagy, promoting cardiac dysfunction and
increased susceptibility to I/R. Similar evidence has also been obtained with tamoxifen-inducible
cardiac-specific Drp1-KO mice [65]. In pig hearts, repetitive myocardial stunning induces autophagy as
a homeostatic mechanism in which apoptosis is inhibited and tissue damage is limited. In fact, in this
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model, heart function fully recovers after normalization of coronary flow, suggesting that autophagy
may promote the survival of hibernating myocardium [144].
A recent study has also suggested a role of mitophagy in HF pathogenesis (Figure 2). By using
heart samples from HF patients and AMPKα2 genetically modified mouse models with transverse
aortic constriction (TAC), researchers have found a serine residue (S495) in PINK1 that undergoes
phosphorylation after exposure to AMPKα2 upon dissipation of the mitochondrial membrane potential
in cardiomyocytes. This process has been found to be essential for the efficient translocation of Parkin to
the mitochondria to increase the rate of mitophagy during HF [66] (Table 1). Moreover, PINK1 protein
levels are markedly reduced in cases of end-stage human HF, indicating inefficient mitophagy [145].
In 2013, Hoshino A demonstrated that the impairment of mitophagy by cytosolic p53 facilitates
HF in mice through binding of p53 to Parkin and subsequent p53 sequestration. This process
impairs the reuse of dysfunctional mitochondria and subsequently induces the development of cardiac
dysfunction [67] (Table 1). Recent studies on KO mouse models have also highlighted a role for
Ulk1-dependent mitophagy in the protection of the heart against pressure overload-induced HF [146].
Coupled with impaired mitophagy, defects in mitochondrial biogenesis (and thus mtDNA
depletion) occur due to downregulation of PGC-1α in the early stages of HF [147]. Moreover, failing
hearts have been found to express depleted levels of nuclear respiratory factor 1 (NRF1), mitochondrial
transcription factor A (TFAM) and estrogen-related receptor α (ERRα), and this reduction in expression
has been demonstrated to negatively impact disease progression [148].
Most of the literature considers autophagy and mitophagy to be mediators of cardioprotection,
especially when mitophagy removes damaged mitochondria; however, paradoxically, as observed
in other heart diseases, several reports have described these pathways as degenerative processes in
the context of HF, since their activation triggers a switch from compensated cardiac hypertrophy to
HF with fibrosis onset [149]. In addition, stress-induced mitophagy in the failing heart is similar to
a maladaptive response to hemodynamic parameters such as pressure overload and contributes to
negative remodeling of the myocardium [150]. This process is mainly mediated by Beclin1 expression,
as heterozygous disruption of Beclin1 in transgenic mice diminishes pathological remodeling.
2.5. Hypertension
HT is a multifactorial disease resulting from multiple causes and mechanisms controlling blood
pressure, as Dr. Irvine H. proposed in a theory named the “mosaic of arterial hypertension” in
1967 [151]. Addressing HT is crucial because it remains a pivotal risk factor for CVDs.
Few studies have focused on mitophagy behavior in hypertensive hearts. In 2015, a study indicated
that the coexistence of obesity and HT aggravates mitochondrial dysfunction, worsening left ventricular
ejection fraction and general clinical outcomes in young animals. In this context, RAAS activation
plays a dual role: it inhibits mitochondrial biogenesis by decreasing PGC-1α, NRF1 and TFAM and
mediates the excessive clearance of mitochondria via mitophagy. The latter may occur following
drastic changes in mitochondrial fission/fusion balance, where the cleavage of OPA1 (increased ratio of
short isoform to long isoform) and the concomitant downregulation of MFN1 enhance mitochondrial
fragmentation. Consequently, these dramatic modifications in mitochondrial turnover aggravate cell
injury [68]. Taken together, these findings suggest that mitophagy may contribute to the development
of hypertensive hearts, and further studies may provide new insights into these mechanisms. Further
evidence derives from a murine model of HT induced by feeding mice a high-salt diet [69]. Spermidine
assumption led to a delayed onset of HT in wild-type animals by stimulating autophagy and mitophagy
in cardiomyocytes; however, spermidine had no beneficial effects in ATG5 KO mice, which lacked
LC3-II and expressed high levels of p62/ Sequestosome 1 (SQSTM1) [69] (Table 1).
In addition to defects in this mitochondrial quality control system, general organelle dysfunction
has been reported to be involved during HT [70,152,153]. At the level of the microvasculature of HT
patients, capillary rarefaction is an important clinical sign to be evaluated. Capillary rarefaction may
be counteracted by the action of endothelial progenitor cells (EPCs) strongly involved in angiogenesis,
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but mitochondrial dysfunction in these cells leads to a significant imbalance between microvasculature
resistance and new vessel formation. Downregulation of the C-X-C motif chemokine receptor 4
(CXCR4)/Janus kinase 2 (JAK2)/sirtuin 5 (SIRT5) signaling pathway is responsible for EPC dysfunction
exacerbating HT in patients; indeed, CXCR4, which is depleted in HT samples, is able to improve
SIRT5-dependent mitochondrial function via JAK2 phosphorylation [70] (Table 1).
We aimed to provide a general overview of mitophagy/autophagy in HT diseases; however, we
found conflicting evidence when considering pulmonary HT (PH), as further summarized in [153].
Briefly, increased levels of LC3-II were detected in almost all disease models (human, rat, mouse). The
role of this increase is controversial, and the upstream (or downstream) mechanism remains unknown.
In two cases, autophagy was considered cardioprotective by reducing vascular remodeling [154,155].
On the basis of other experimental data, autophagy was classified as detrimental since its ablation
promoted angiogenesis and attenuated HF and HT [156,157].
2.6. Arrhythmia
Arrhythmia is a condition in which electric signals that allow the heart to beat do not work
properly. Since electrical propagation supports proper cardiac function, arrhythmia can be fatal in some
circumstances [158]. Thus far, there is no direct evidence linking defective mitophagy to the onset of
this pathology, but mitochondria play key functional roles that depend on the amounts of ATP and ROS
produced. Indeed, decreased ATP content and increased ROS generation negatively affect the electrical
conduction of the heart through intracellular ion balance disruption [159], introducing heterogeneity
in cardiac action potentials. The first link between mitophagy and proarrhythmic disturbances was
revealed in 2019 in a study by Murphy KR and colleagues, who found that decreases in mitophagy due
to aging lead to mitochondrial depolarization, ROS overproduction and consequent ryanodine receptor
2 (RyR2) oxidation; these changes induce altered and increased spontaneous Ca2+ waves (SCWs),
enhancing the probability of arrhythmia [71] (Table 1). These findings have been further confirmed
by the findings that ATG7 overexpression and Torin1 treatment restored mitochondrial polarization,
normal ROS production and normal SCWs. For this reason, proper activation of the mitophagic (or
autophagic) pathway could eliminate damaged organelles by preserving cell homeostasis.
2.7. Congenital Heart Disease
The incidence of moderate-to-severe structural congenital heart disease (CHD) in liveborn infants
is 6 to 8 per 1000 live births; 3 per 1000 live births have heart disease that results in death or requires
cardiac catheterization or surgery during the first year of life.
Recently, some authors [160,161] have found that anomalies in cilia function are implicated in
CHDs. Cilia are hair-like organelles that can be found on the surfaces of different types of cells. They
perform various functions, such as functions related to cell signaling, extracellular fluid propulsion
and cell cycle control. The literature reports that motile and immotile cilia are required to establish
left-right identity in developing embryos. During heart development, the most important role for cilia
is establishing left-right asymmetry and determining the direction of heart looping [161]. Burkhalter
MD reported a link between cilia and mitochondrial function during the development of heterotaxy
syndromes. Impairment of mitochondrial function results in longer cilia, while shorter cilia are
generated when organelle activity is enhanced. Interestingly, he also found a significant reduction in
mtDNA in a cohort of heterotaxy patients [160]. Some important reports have provided proof of an
association between autophagy and cilia length; in detail, cilia elongation depends on mTOR pathway
suppression and thus autophagy activation, which enables suppression of proteasomal degradation of
the proteins that constitute cilia [162–164].
Since autophagy is known to be involved in cardiomyocyte differentiation [165], impairment of
this process may be the cause of some CHDs.
J. Clin. Med. 2020, 9, 892 14 of 26
2.8. Peripheral Vascular Disease
Peripheral vascular disease (PVD) is a disorder of arteries and veins that causes pain and fatigue,
often during physical exercise; however, damage to the vessel structure does not necessarily occur.
VSMCs are the primary constituents of blood vessels, and they play very important roles, of which their
capacity to transform into macrophage-like and osteochondrogenic-like cells is especially important.
Several lines of evidence support the hypothesis that genetic reprogramming in VSMCs occurs
when peripheral vessels become damaged [166]. VSMCs are currently believed to be exposed to
autophagic stimuli such as oxidants, cytokines, ox-LDL and growth factors during PVD (i.e., after
percutaneous coronary intervention) and that this molecular cascade determines the conversion of
these cells to a macrophage-like phenotype, while the osteochondrogenic type is suppressed [167].
Thus, autophagy appears to be a regulator of the cell response to injury. In the most common PVD,
deep venous thrombosis (DVT), ATG5 plays a critical role in the progression of the pathology since it
mediates thrombus recanalization, acting mainly on endothelial cells. In this context, ATG5 activates
Akt phosphorylation, which is counteracted by the use of 3-methyladenine (3-MA); 3-MA inhibits
autophagy by lowering ATG5 levels and concomitantly inhibiting endothelial cell migration and tube
formation [168]. Strong evidence of the role of autophagy in promoting angiogenesis has also been
derived from other studies on pathologies requiring considerable tissue-remodeling programs, such
as cancers, and from findings following the pharmacological inhibition of this pathway. Indeed, the
enhanced presence of lysosome-associated membrane protein (LAMP) and cathepsin D drives robust
angiogenesis in the context of infantile hemangioma [169,170]. Otherwise, chronic expression of ATG5
induces cell death.
Patients with peripheral artery disease usually present with decreased mobility, which cannot be
explained only by ischemia-related events or pain. Many reports that have focused on muscle fiber types
and their distributions in PVD patients compared to non-PVD participants have reported impaired
mitochondrial respiration, enhanced oxidative stress and loss of intermyofibrillar mitochondria [72]. In
addition, excessive mitophagy has been detected in parallel with the loss of compensatory mechanisms,
such as PGC-1α overexpression. This uncontrolled and dysfunctional mitochondrial removal is
independent of age and has been evaluated by direct assessment of LC3-II increases in fibers [72]
(Table 1). Although further experiments are needed to fully address the causes and consequences
associated with mitophagy, the findings thus far may help to guide research towards new treatments
for this group of diseases. For further details, please also refer to [121].
2.9. Mitophagy in Human Cardiac Surgery
Nevertheless, many people are subjected to cardiac surgery involving coronary artery bypass
grafting (CABG), and despite the use of cardioplegic solutions to preserve heart function, I/R remains
one of the main challenges in this periprocedural setting.
In 2013, a descriptive paper reported that the heart of patients undergoing CABG activates the
homeostatic intracellular repair response (HIR) program, a prevailing aspect of which is autophagy
activation [171]. In heart samples from 19 patients, p62, Beclin1, ATG5 and LC3-II degradation
were recorded, suggesting an increased autophagic flux [171]. The same authors later asserted that
mitophagy and mitochondrial biogenesis also take part in the HIR program by increasing their
activation following cardiac surgery [73]. Despite the innovative approach and use of human samples
in these studies, additional studies should further confirm this evidence because autophagy and
mitophagy are complex and difficult to assess in tissues. For example, the low levels of LC3-II detected
in the first study [171] indicate both low autophagy induction and increased flux without protein
replacement. In the second paper [73], mitophagy activation was inferred from Parkin translocation
from the cytosol to mitochondria in heart samples before and after surgery and from decreased levels
in optineurin (OPTN) and NDP52 receptors in the total homogenate; however, the translocation of
these proteins into mitochondria and their clustering should be evaluated. Notably, a high percentage
of patients being analyzed might be under statin treatment, which induces autophagy itself [172].
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Nevertheless, mitophagy activation during CABG, assessed by FUNDC1 dephosphorylation, has
also been reported by a second independent group, but this was described as a deleterious event in the
follow-up of patients as it caused platelet aggregation and increased risk of thrombosis [74].
3. Targeting Mitophagy for Cardioprotection
As a mechanism critical for mitochondrial quality control, mitophagy is essential for the
establishment of a healthy mitochondrial population inside cells. We have discussed how disruption
of mitophagic and autophagic pathways exacerbates the development of heart diseases, but it is
important to understand how these pathways modulate heart diseases for therapeutic purposes.
Various chemical reagents, drugs and natural compounds are able to modulate mitophagy (Table 2),
and studies on their use in therapies are in progress.
Table 2. Summary of compounds that provide significant cardioprotection via mitophagy regulation.
Compound Target/Mechanism of Action Cardiovascular Effect
TEMPOL SOD mimetic/reduces ROS and counteractsage-related mitophagy
Improves preconditioning after
hypoxia/reoxygenation in aged cultured
cardiomyocytes
Simvastatin mTOR-dependent activation of mitophagythrough Parkin and p62/SQSTM1
Improves cardioprotection during left
ventricular artery occlusion and reperfusion
Zinc Favors SOD activity and activatesPINK1/Beclin1-dependent mitophagy
Improves the recovery of cultured
cardiomyocytes after
hypoxia/reoxygenation
Liraglutide Agonist of GLP1, stimulates SIRT1 andpromotes Parkin-mediated mitophagy
Promotes recovery after left ventricular
artery ligation-induced ischemia
Melatonin
Inhibits Mst1 phosphorylation, increases
LC3-II levels and enhances
Parkin-mediated mitophagy
Counteracts diabetic CM
Metformin Activates autophagy by disrupting theBcl2-Beclin1 complex
Inhibits cardiomyocyte apoptosis in
diabetic heart
TEMPOL: 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl; SOD: superoxide dismutase 1; ROS: reactive oxygen
species; SQSTM1: Sequestosome 1; PINK1: PTEN Induced Kinase 1; GLP1: Glucagon Like Peptide 1; SIRT1: Sirtuin
1; LC3-II: Microtubule Associated Protein 1 Light Chain 3 II; CM: cardiomyopathy.
Polyphenols are plant-derived compounds that offer many health benefits. Recent studies
have revealed the ability of these compounds to alter mitophagy via different signaling pathways;
for example, resveratrol and quercetin act on FOXO3a signaling and promote PINK1 and Parkin
overexpression [173], curcumin regulates transcription factor EB (TFEB) activity via the inhibition
of mTORC1 [174], and melanoidin activates mitophagy by increasing the levels of Beclin1 [175].
The mTOR pathway is also the target of a drug belonging to the statin class, simvastatin, which
inhibits cholesterol biosynthesis. Simvastatin acts on the mitochondrial translocation of Parkin and
p62/SQSTM1 to increase mitophagy and autophagy [172], which is required for cardioprotection.
On the other hand, also excessive and persistent mitophagy can also be deleterious; in this context,
Parkin, PINK1 and Beclin1 proteins may be upregulated. This upregulation can be counteracted
by multiple types of treatments, such as those involving the use of the superoxide dismutase (SOD)
mimetic 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-oxyl (TEMPOL) and mitoTEMPOL [176,177], which
counteract age-related mitophagy impairment associated with diseases. Other modulators of mitophagy
mediators are zinc [178] and liraglutide [179]. Zinc is able to ensure proper mitophagic pathway
signaling through PINK1 and Beclin1 by limiting ROS generation and mitochondrial membrane
potential dissipation, while liraglutide, an agonist of the glucagon-like peptide 1 (GLP1) receptor,
upregulates the sirtuin 1 (SIRT1) pathway, promoting Parkin-mediated mitophagy, and has already
been validated as a molecule useful for the repair of infarcted hearts. Another SIRT1 activator with
similar effects related to mitophagy and cardioprotection is nicotinamide [180].
Among all the antioxidants mentioned so far, melatonin plays a very important role in
cardioprotection. Although melatonin is known to be a master regulator of cell death and
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inflammation [181], a few studies have reported its roles in inducing autophagy [182,183] and
mitophagy during CVDs. In addition to the two studies mentioned in the “Atherosclerosis” and
“Cardiomyopathies” sections [53,63], other studies have been conducted on ischemia and reperfusion
conditions, during which mitochondrial fission is activated and the PTPC is in its open state [184].
Another study reported upregulation of the PINK1/Parkin pathway and cell death mediated by
mitophagy [185]. These (perhaps apparently) controversial results require further research in the
field to clearly evaluate the molecular mechanisms associated with cardioprotection. Similarly, the
link between PTPC activity and mitophagy/autophagy has not yet been fully addressed [91,186].
Mitochondrial dynamics are strongly linked to mitophagy; consequently, therapies targeting proteins
involved in fission or fusion may also act on mitophagy. Mfn2, which is essential for mitochondrial
fusion, has also been found to be a receptor for Parkin recruitment to mitochondria that should undergo
mitophagy [131]; this process is regulated by PINK1 phosphorylation involving the T111/S442 residues,
the simultaneous mutation of which prevents functional interactions between Mfn2 and Parkin. The
absence of Mfn2 prevented Parkin translocation and thus mitophagy [131]. Mfn2 mutations are
reportedly able to cause diseases such as the neurodegenerative Charcot Marie Tooth type 2A, and the
use of agonists to improve Mfn2 actions reverses mitochondrial dysfunction [187]. Mfn2 can also be
phosphorylated at S378 by PINK1, and this phosphorylation site is essential to its functions. Therefore,
Mfn2 agonists may also act on mitophagy as well as mitochondrial fusion to counteract the negative
effects of the disease.
4. Future Perspectives and Conclusions
The crucial role of mitochondria in cardiac function is well established; thus, a fine balance
between the removal of dysfunctional mitochondria and their replacement with new organelles is
needed. Overall, induction of mitophagy is seen as a cardioprotective mechanism started by the heart
to protect itself from different types of damage, but to what extent (coupled to the setting) mitophagy
may be beneficial and the circumstances in which it can be considered detrimental are not yet clear. In
addition, the heart is characterized by three different mitochondrial subpopulations, and it would be
interesting to understand whether there are differences in mitophagy among these subpopulations
and the purpose of these differences. Therefore, a threefold evaluation of mitochondrial dynamics,
biogenesis and PTPC opening should be considered when examining mitophagy.
The proper use of disease animal models combined with cardiac-specific deletion of proteins
involved in such pathways and in-depth analysis of human samples may provide further insights
to address conflicting evidence and unanswered questions. Recent important findings highlight
the role of microRNA (miR)-dependent regulation of gene expression in cardiac protection and
repair [188]. An interesting association between miRs and mitophagy has also been reported. Under
experimental I/R conditions, upregulation of miR-410 and concomitant loss of mitophagy have
been found to occur [189]; under these circumstances, miR-410 was associated with decreased
cell viability and severe mitochondrial impairment, which may occur via direct interaction with
HMGB1 and subsequent mitophagy inhibition. A second miR (miR-137) has also been detected to
be overexpressed under the same conditions; this miR is able to downregulate Nix and FUNDC1,
impairing mitophagy [190]. Therefore, controlling and monitoring the expression of miRs may be an
added value for cardioprotective therapies.
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